Literature DB >> 16733347

Molecular pathogenetics of renal cancer.

Andreas A Skolarikos1, Athanasios G Papatsoris, Gerasimos Alivizatos, Charalambos Deliveliotis.   

Abstract

Recent developments in genetics and molecular biology have led to an increased understanding of the pathobiology of renal cancer. Thorough knowledge of the molecular pathways associated with renal cancer is a prerequisite for novel potential therapeutic interventions. Studies are ongoing to evaluate novel anticancer agents that target specific molecular entities. This article reviews current knowledge on the genetics and molecular pathogenesis of sporadic and inherited forms of renal cancer. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16733347     DOI： 10.1159/000093631

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN： 0250-8095            Impact factor:   3.754


  7 in total

1.  Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.

Authors:  Michalis Liontos; Eleni-Andriana Trigka; Penelope Korkolopoulou; Kimon Tzannis; Giorgos Lainakis; Konstantinos Koutsoukos; Efthymios Kostouros; Maria Lykka; Christos N Papandreou; Vassilis Karavasilis; Christos Christodoulou; Athanasios Papatsoris; Andreas Skolarikos; Ioannis Varkarakis; Ioannis Adamakis; Christos Alamanis; Konstantinos Stravodimos; Dionysios Mitropoulos; Charalambos Deliveliotis; Constantinos A Constantinidis; Angelica Saetta; Efstratios Patsouris; Meletios Α Dimopoulos; Aristotelis Bamias
Journal:  World J Urol       Date:  2016-07-09       Impact factor: 4.226

Review 2.  Novel biomarkers of acute kidney injury: Evaluation and evidence in urologic surgery.

Authors:  Marianne Schmid; Deepansh Dalela; Rana Tahbaz; Jessica Langetepe; Marco Randazzo; Roland Dahlem; Margit Fisch; Quoc-Dien Trinh; Felix K-H Chun
Journal:  World J Nephrol       Date:  2015-05-06

Review 3.  Tivozanib: current status and future directions in the treatment of solid tumors.

Authors:  Sumanta K Pal; Paulo G Bergerot; Robert A Figlin
Journal:  Expert Opin Investig Drugs       Date:  2012-09-26       Impact factor: 6.206

4.  DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies.

Authors:  Inga Peters; Natalia Dubrowinskaja; Mahmoud Abbas; Christoph Seidel; Michael Kogosov; Ralph Scherer; Kai Gebauer; Axel S Merseburger; Markus A Kuczyk; Viktor Grünwald; Jürgen Serth
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

5.  The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.

Authors:  Sung Han Kim; Weon Seo Park; Eun Young Park; Boram Park; Jungnam Joo; Jae Young Joung; Ho Kyung Seo; Kang Hyun Lee; Jinsoo Chung
Journal:  PLoS One       Date:  2017-06-27       Impact factor: 3.240

6.  Analysis of the concordance of 20 immunohistochemical tissue markers in metastasectomy lesions in patients with metastatic renal cell carcinoma: A retrospective study using tissue microarray.

Authors:  Sung Han Kim; Weon Seo Park; Eun Young Park; Jungnam Joo; Jinsoo Chung
Journal:  Investig Clin Urol       Date:  2020-05-25

7.  Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response.

Authors:  Natalia Dubrowinskaja; Kai Gebauer; Inga Peters; Jörg Hennenlotter; Mahmoud Abbas; Ralph Scherer; Hossein Tezval; Axel S Merseburger; Arnulf Stenzl; Viktor Grünwald; Markus A Kuczyk; Jürgen Serth
Journal:  Cancer Med       Date:  2014-01-27       Impact factor: 4.452
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.